17β-HSD

17beta-HSD; 17β-hydroxysteroid dehydrogenases; 17 beta-hydroxysteroid dehydrogenase

17β-HSD (17β-Hydroxysteroid Dehydrogenases) is a class of NADPH/NAD+ dependent oxidoreductases that primarily catalyze the reversible conversion between the 17β-hydroxyl and ketone groups of steroid hormones, playing a crucial role in the synthesis, activation, and inactivation of steroids. The 17β-HSD family mainly belongs to the short-chain dehydrogenase/reductase (SDR) family, with the exception of 17β-HSD5 (AKR1C3), which belongs to the aldo-keto reductase (AKR) family. To date, 14 different mammalian 17β-HSDs have been identified, of which 12 are expressed in human tissues, exhibiting diverse tissue distributions, subcellular localizations, and catalytic preferences (oxidation or reduction).
17β-HSD1 primarily catalyzes the conversion of estrone (E1) to estradiol (E2) and is associated with breast cancer, prostate cancer, and endometriosis. 17β-HSD2 catalyzes the oxidation of E2 to E1, while also regulating the interconversion between androstenedione (A4) and testosterone (T), playing a role in osteoporosis. 17β-HSD3 promotes the conversion of A4 to T and is crucial for male sexual differentiation. 17β-HSD4 is involved in fatty acid β-oxidation and steroid hormone inactivation. Additionally, 17β-HSD5 participates in steroid hormone and prostaglandin synthesis, whereas 17β-HSD7 is involved in cholesterol and estrogen biosynthesis. 17β-HSD10 exhibits broad substrate specificity, contributing to the metabolism of fatty acids, bile acids, and neurosteroids, and has been implicated in Alzheimer's disease (AD). The development of selective inhibitors targeting specific 17β-HSD isoforms has become an important strategy in related disease research^[1].

References:

[1]. Marchais-Oberwinkler S, et al. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development. J Steroid Biochem Mol Biol. 2011 May;125(1-2):66-82. [Content Brief]

17β-HSD Related Products (128):

By Effects:	Inhibitors (124) Activator (1) Modulator (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-162209

HSD17B13-IN-63	Inhibitor
HSD17B13-IN-63 (Compound 160) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-63 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-163254

HSD17B13-IN-57	Inhibitor
HSD17B13-IN-57 (Compound 93) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-57 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-163242

HSD17B13-IN-28	Inhibitor
HSD17B13-IN-28 (compound? 47) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-28? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).

HY-161277

HSD17B13-IN-100	Inhibitor
HSD17B13-IN-100 (compound 34) is an inhibitor of HSD17B13 and has IC₅₀ with estradiol ＜0.1 μM.

HY-163263

HSD17B13-IN-80	Inhibitor
HSD17B13-IN-80 (Compound 151) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-157667

HSD17B13-IN-44	Inhibitor
HSD17B13-IN-44 (Compound 23) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-44 can be used for research on liver diseases or metabolic disorders.

HY-157671

HSD17B13-IN-45	Inhibitor
HSD17B13-IN-45 (Compound 195) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-45 can be used for research on liver diseases or metabolic disorders.

HY-163264

HSD17B13-IN-81	Inhibitor
HSD17B13-IN-81 (Compound 154) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-81 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-161225

HSD17B13-IN-40	Inhibitor
HSD17B13-IN-40 (compound 6) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-40? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).

HY-163255

HSD17B13-IN-58	Inhibitor
HSD17B13-IN-58 (96) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.

HY-157662

HSD17B13-IN-33	Inhibitor
HSD17B13-IN-33 (Compound 115) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-33 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-163244

HSD17B13-IN-30	Inhibitor
HSD17B13-IN-30 (compound 64) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-30? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).

HY-129433

17β-HSD1-IN-2	Inhibitor
17β-HSD1-IN-2 (PBRM) is a non-estrogenic and steroidal covalent irreversible inhibitor of 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) (K_i=368 nM). 17β-HSD1-IN-2 can be used for the research of estrogen-dependent disorders.

HY-161215

HSD17B13-IN-14	Inhibitor
HSD17B13-IN-14 (Compound 4) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-14 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI).

HY-163252

HSD17B13-IN-53	Inhibitor
HSD17B13-IN-53 (Compound 88) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-53 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-157676

HSD17B13-IN-47	Inhibitor
HSD17B13-IN-47 (Compound 500) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-47 can be used for research on liver diseases or metabolic disorders.

HY-163266

HSD17B13-IN-83	Inhibitor
HSD17B13-IN-83 (Compound 150) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-83 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-163259S

HSD17B13-IN-62-d₃	Inhibitor
HSD17B13-IN-62-d3 (176) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.

HY-163246

HSD17B13-IN-34	Inhibitor
HSD17B13-IN-34 (75) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.

HY-163253

HSD17B13-IN-56	Inhibitor
HSD17B13-IN-56 (Compound 89) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

Name
Email *

	Sorry, but the email address you supplied was invalid.